Treatment Patterns, Testing Practices, and Outcomes in Patients with
EGFR mutation
brain metastases
non-small-cell lung cancer
real-world data
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
24
01
2023
revised:
19
02
2023
accepted:
22
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
Non-small-cell lung cancer (NSCLC) represents 85% of new cases of lung cancer. Over the past two decades, treatment of patients with NSCLC has evolved from the empiric use of chemotherapy to more advanced targeted therapy dedicated to patients with an epidermal growth factor receptor (
Identifiants
pubmed: 36900371
pii: cancers15051581
doi: 10.3390/cancers15051581
pmc: PMC10000701
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AstraZeneca (Poland)
ID : NCT04031898
Références
J Thorac Oncol. 2020 Aug;15(8):1271-1276
pubmed: 32718535
Clin Cancer Res. 2012 Aug 15;18(16):4406-14
pubmed: 22733536
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S265-S279
pubmed: 31857950
J Thorac Oncol. 2014 Feb;9(2):195-9
pubmed: 24419416
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Oncol. 2021 Nov;59(5):
pubmed: 34558640
Clin Cancer Res. 2011 Mar 15;17(6):1616-22
pubmed: 21135146
Rep Pract Oncol Radiother. 2012 Sep 05;17(5):281-7
pubmed: 24669309
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Ther Adv Med Oncol. 2021 Nov 29;13:17588359211059874
pubmed: 35173817
Cancer Drug Resist. 2021 Apr 27;4(3):740-744
pubmed: 35582308
Ann Oncol. 2018 Mar 1;29(3):687-693
pubmed: 29293889
Sci Rep. 2021 Nov 30;11(1):23140
pubmed: 34848786
Adv Ther. 2020 Feb;37(2):946-954
pubmed: 31955357
Lung Cancer (Auckl). 2017 Oct 24;8:191-206
pubmed: 29123433
Front Oncol. 2014 Dec 08;4:350
pubmed: 25538894
Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509
pubmed: 34408792
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
Drugs Real World Outcomes. 2021 Dec;8(4):537-545
pubmed: 34533784
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Curr Probl Cancer. 2020 Jun;44(3):100570
pubmed: 32498966
Cancer. 2010 Mar 1;116(5):1336-43
pubmed: 20066717
Nat Rev Dis Primers. 2015 May 21;1:15009
pubmed: 27188576
PLoS One. 2019 Jan 4;14(1):e0209709
pubmed: 30608948
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Anticancer Res. 2022 May;42(5):2583-2590
pubmed: 35489768
Clin Transl Oncol. 2018 Feb;20(2):150-159
pubmed: 28616720
J Clin Oncol. 2021 Mar 20;39(9):1040-1091
pubmed: 33591844
Oncologist. 2022 Mar 4;27(2):87-e115
pubmed: 35641222
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Onco Targets Ther. 2017 May 05;10:2473-2482
pubmed: 28503070
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Cancer. 2005 Jun 1;103(11):2344-8
pubmed: 15844174
Lung Cancer. 2020 Feb;140:71-79
pubmed: 31884129
Lung Cancer. 2015 Dec;90(3):509-15
pubmed: 26494259
Ann Transl Med. 2019 Feb;7(3):61
pubmed: 30906765